These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9476928)

  • 1. Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
    Gulec SA; Serafini AN; Sridhar KS; Peker KR; Gupta A; Goodwin WJ; Sfakianakis GN; Moffat FL
    J Nucl Med; 1998 Feb; 39(2):243-5. PubMed ID: 9476928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid.
    Tisell LE; Ahlman H; Wängberg B; Kölby L; Fjälling M; Forssell-Aronsson E; Mölne J; Nilsson O
    Br J Cancer; 1999 Mar; 79(9-10):1579-82. PubMed ID: 10188909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of somatostatin receptors in thyroid neoplasia.
    Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
    Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
    Adrian HJ; Dörr U; Bach D; Bihl H
    Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature.
    Kostoglou-Athanassiou I; Pappas A; Gogou L; Kaldrymides P
    Horm Res; 2003; 60(4):205-8. PubMed ID: 14530610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs.
    Teunissen JJ; Kwekkeboom DJ; Krenning EP
    Trends Endocrinol Metab; 2006; 17(1):19-25. PubMed ID: 16311041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
    Dörr U; Sautter-Bihl ML; Bihl H
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
    [No Abstract]   [Full Text] [Related]  

  • 11. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.
    Chen CC; Czerwiec FS; Feuillan PP
    J Nucl Med; 1998 Feb; 39(2):238-40. PubMed ID: 9476926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intense FDG uptake in a benign Hurthle cell adenoma.
    Rohren EM
    Clin Nucl Med; 2004 Oct; 29(10):664-6. PubMed ID: 15365450
    [No Abstract]   [Full Text] [Related]  

  • 14. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
    Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H
    Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
    Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
    J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is a false-positive somatostatin receptor scintigraphy?
    Reubi JC
    J Nucl Med; 1998 Dec; 39(12):2193-4. PubMed ID: 9867170
    [No Abstract]   [Full Text] [Related]  

  • 17. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy.
    Becker W; Schrell U; Buchfelder M; Hensen J; Wendler J; Gramatzki M; Wolf F
    Nuklearmedizin; 1995 Jun; 34(3):100-3. PubMed ID: 7630741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Roser HW; Bockisch A
    Thyroid; 2001 Jul; 11(7):647-59. PubMed ID: 11484893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
    Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
    Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
    Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
    Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.